Efficacy and Safety of Tocilizumab for TAO
Tocilizumab, Thyroid Associated Ophthalmopathy
About this trial
This is an interventional treatment trial for Tocilizumab focused on measuring Thyroid Associated Ophthalmopathy, tocilizumab
Eligibility Criteria
Inclusion criteria: Age 18-70 years old Clinical diagnosis of Thyroid-associated ophthalmopathy Euthyroid status at least 1 months before baseline. No previous specific therapy for TAO, except for local measures Written informed consent is obtained Exclusion criteria: Uncontrolled diabetes or hypertension Renal or hepatic insufficiency. Infectious diseases (HIV, HBV,TB and so on) History of mental/psychiatric disorder Other ocular diseases or fundus diseases. Any previous systemic medications or surgery for the treatment of TAO Pregnant or lactating females. Intolerability of tocilizumab
Sites / Locations
- Zhongshan Ophthalmic CenterRecruiting
Arms of the Study
Arm 1
Experimental
tocilizumab
administrated with tocilizumab (8mg/kg) every four weeks